Navigation Links
Chronic pain: Watch out before accepting diagnosis and treatment
Date:9/8/2011

Bethesda, MDA new commentary published online in The FASEB Journal (http://www.fasebj.org) argues that patients should be diligent and demand proof of safety and benefit before beginning any treatment regimen for chronic pain, as some treatments have very little scientific evidence that they actually alleviate the conditions for which they are prescribed. In the article, Phillip J. Baker, Ph.D., Executive Director of the American Lyme Disease Foundation, dispels myths surrounding chronic Lyme disease, using it as an example of why patients should ensure that diagnostic and treatment tools are approved by the Food and Drug Administration and not just recommended by other patients and physicians.

"Despite repeated warnings by the Centers for Disease Control and Prevention and the Food and Drug Administration, the diagnosis of chronic Lyme disease often is based on the false results of non-standard test procedures, not approved by the FDA," said Baker. "This is inexcusable since 46 FDA-approved tests are available and used routinely by various state public health laboratories. A false diagnosis can result in patients being placed on prolonged antibiotic therapy or some other unproven and potentially harmful remedy."

Baker also says that before agreeing to undergo any treatment regimen for chronic pain, patients should ask their physician to provide results from published, placebo-controlled studies proving that the proposed remedy is both beneficial and safe. Testimonials by previously treated patientsregardless of the numberare not sufficient proof of benefit and safety. Unapproved and undocumented treatments are usually not covered by health insurance and therefore result in a huge financial burden to the patient. Chronic Lyme disease must be considered as part of a broad-based, multidisciplinary effort to understand the cause and treatment of chronic pain in general as outlined by the Institute of Medicine's report, "Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research" (http://www.iom.edu/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx).

"When doctors don't know what's causing a patient to experience chronic pain, desperation can set in," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "That desperation, however, is no excuse for pushing the boundaries of the Hippocratic Oath by diagnosing a patient with a poorly defined health condition, like chronic Lyme disease, for which the only remedies are unproven and may only cause more harm."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Vitamin E shows possible promise in easing chronic inflammation
2. New research lights up chronic bacterial infection inside bone
3. When acute hepatitis develops into chronic hepatitis
4. Research uncovers promising target to treat chronic abdominal pain
5. New trigger for chronic inflammation in rheumatoid arthritis discovered
6. Early-life experience linked to chronic diseases later in life: UBC research
7. NHLBI awards $11 million for molecular roadmap to chronic lung diseases
8. New potential to treat chronic obstructive pulmonary disease
9. Higher opioid dose linked to overdose risk in chronic pain patients
10. Discovery of new type of immune cells regulating inflammation in chronic diseases
11. New data on highly effective treatment for chronic rhinosinusitis with nasal polyps
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... LONDON , Feb. 7, 2017 Report ... $12.5 billion by 2021 from $8.3 billion in 2016 ... from 2016 to 2021. Report Includes - An ... of global market trends, with data from 2015 and ... through 2021. - Segmentation of the market on the ...
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a ... a new white paper " What You Should Know ... problem of ensuring user authenticity is a growing concern. ... authentication of users. However, traditional authentication schemes such as ... Biometric authentication offers an elegant solution to ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... -- Four US Biotech equities have been ... are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), Arrowhead Pharmaceuticals Inc. ... and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT ). ... are growing more bullish on the sector as a ... cash held overseas for tax reason by large US ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences ... Spain has been appointed as a Certified ... The IsoFlux system will be used in Genetracer Biotech,s ... to lung and colon cancer, with plans to move ... laboratory is utilizing Fluxion,s IsoFlux System to isolate, recover, ...
(Date:2/27/2017)... ... February 27, 2017 , ... The Catalyst Midwest premix manufacturing ... Midwest offering premix services and private label organic services. , The first organic product ... Zamzow, chief operating officer of Dynamite Marketing, which owns the facility. , Catalyst already ...
(Date:2/25/2017)... ... February 25, 2017 , ... The ... in an ongoing effort to create meaningful change by increasing communication, partnerships ... with emphasis on consumers and patients’ mental health well-being. , Both organizations are ...
Breaking Biology Technology: